Diskussion zur BICO Group Aktie WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: Hedgehog3

Junge,das ist ein Langzeitinvest,ansonsten hast du dich nicht ordentlich informiert,bevor du gekauft hast. Entweder hast du die Geduld oder verkaufst. Aber jedes Mal das Gejammer zu lesen, nervt

Sartorius mit guten Zahlen, hoffentlich Bico dann auch!!!

BICO Group BICO’s Calendar for financial reporting: H2 2024 and 2025 BICO Group AB 559050–5052 (NASDAQ STOCKHOLM: BICO) BICO’s Calendar for financial reporting: H2 2024 and 2025 Q3 report 2024: November 26, 2024, 7am CET Year-end report 2024: February 19, 2025, 7am CET Annual Report 2024: March 20, 2025, to be released during the day Q1 report 2025: April 29, 2025, 7am CEST Annual General Meeting 2025: May 8, 2025. Time to be announced in notice to AGM 2025 Q2 report 2025: August 19, 2025, 7am CEST Q3 report 2025: November 4, 2025, 7am CET Year-end report 2025: February 10, 2026, 7am CET Please note that, as communicated during the Capital Markets Day and due to the new business area structure, BICO’s Q3 report 2024 will be released on Tuesday November 26, 2024, at 7am CET. For further information, please contact: Jacob Thordenberg, CFO, BICO Group AB Phone: +46 735 34 88 84 E-mail: jt@bico.com The information was submitted for publication, through the agency of the contact person set out above, on October 18, 2024 at 7am CEST. BICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 46,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 12,000 publications. Operating through three business areas – Lab Automation, Life Science Solutions, and Bioprinting – BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Alle anstehenden Finanz-Termine bis zur Fälligkeit der Anleihe am 19.03.2026.

Auf jedenfall stabile Seitenlinie 💪🏻 Bico

Wenn sie keine so extrem große Stückelung hätte, würde ich derzeit lieber in die BICO-Anleihe investieren. 18,5% Rendite p.a. auf SEK-Basis, wo bekommt man das schon? Und irgendeine Anschlussfinanzierung wird der CFO bis zum Ablauf am 19.03.26 ja wohl hinbekommen.

Würde eher bei 2,00 € sagen.

Heul doch

Ein kauf drängt sich derzeit nicht auf. Risikobehaftete Anleger können bei 2,95€ über einen kauf nachdenken

Und wieder alles grün im Depot außer bico

Danke . Dir Hoffnung stirbt zuletzt ✊🏻✊🏻✊🏻😅

Das ist die neue, auf dem Strategy Update vorgestellte Ausrichtung/Einteilung der Geschäftsbereiche: Bioprinting unverändert zu vorher, Lab Automation = Biosero, Life Science Solutions = alle snderen Tochterunternehmen.

BICO ist in den drei Geschäftsbereichen Lab Automation, Life Science Solutions und Bioprinting aktiv. Kann mir einer aus der Forum den Bereich Life Science Solutions näher erklären? Darunter kann ich mir immer noch nichts vorstellen

Hier hast Du mal wieder was... aber wohl eher nicht ganz so spektakulär, wie von Dir erhofft, fürchte ich... 😉

BICO Group BICO Group AB’s Nomination Committee for the 2025 Annual General Meeting BICO Group’s major owners have appointed a Nomination Committee and the Annual General Meeting of BICO Group AB will be held on Thursday May 8, 2025. In accordance with the decision by the Annual General Meeting 2024 when the most recently adopted principles regarding the composition of the nomination committee was made, the Nomination Committee of BICO Group AB shall consist of four members appointed by the largest shareholders. The Chairman of the Board shall not be a member of the Nomination Committee but shall normally be co-opted to the meeting of the Nomination Committee. The four largest shareholders who wish to participate in the committee are entitled to appoint one member each. In preparation for the 2025 Annual General Meeting the members of the Nomination Committee have been appointed based on the ownership structure as of September 30, 2024, and consists of: Erik Gatenholm, nominated by himself Jens M. Artelt, nominated by Sartorius Lab Holding GmbH Malin Björkmo, nominated by Handelsbanken Fonder (Chairperson of the Nomination Committee) Héctor Martínez, nominated by himself Rolf Classon, Chairman of the Board of BICO Group AB (co-opted) Shareholders having appointed members to the Nomination Committee represent approximately 51 percent of the voting rights for all shares of BICO Group AB. The Nomination Committee has also appointed Malin Björkmo as Chairperson of the Nomination Committee. The Nomination Committee will prepare proposals for the Annual General Meeting 2025 regarding election of chairman/woman and other directors of the board, election of auditor, matters regarding fees, election of chairman/woman of the Annual General Meeting and resolution concerning the Nomination Committee. Shareholders who wish to submit proposals to the Nomination Committee ahead of the Annual General Meeting 2025 are welcome to contact the Nomination Committee by email: ir@bico.com. Please write “To the Nomination Committee” in the subject line or per mail: BICO Group AB att. Nomination Committee Långfilsgatan 9 412 77 Gothenburg Sweden Proposals shall be submitted in writing in due time before the Annual General Meeting, no later than January 31, 2025, to ensure that the proposals can be considered by the Nomination Committee. For more information, please contact: Rolf Classon, Chairman of the Board, BICO Group AB Phone: BICO Investor Relations +46 735 46 57 77 E-mail: ir@bico.com